The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
Once upon a time, Amy Schumer was one of the countless stars falling in line for the Ozempic craze, but, despite losing 30 ...
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...
Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.
Study looks at benefits and risks to popular weight-loss drugs; Kentucky leads nation in use of them
By Melissa Patrick and Liberty Gilbert Kentucky Health News Whether it is prescribed for diabetes or weight loss, Ozempic and ...
Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback